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Abstract
Background: Mutations of the BRAF gene are the most common genetic alteration in melanoma.
Moreover, BRAF mutations are already present in benign nevi. Being overexpressed and mutated,
B-Raf is a potential target for the immune system and as this mutation seems to be an early event,
a humoral immune response against this antigen might serve as a diagnostic tool for detection of
high risk patients.
Methods: 372 sera of 148 stage IV melanoma patients and 119 sera of non-melanoma patients
were screened for B-Raf, B-Raf V599E and C-Raf specific antibodies by an ELISA assay. Sera were
screened for specific total Ig and for IgG. Serum titers were compared with a two tailed Mann-
Whitney U test. Sera with titers of 1:300 or higher were termed positive and groups were
compared with a two tailed Fisher's exact test.
Results: B-Raf specific antibodies recognizing both B-Raf and B-Raf V599E were detected in 8.9%
of the sera of melanoma patients and in 2,5% of the control group. Raf specific IgG was detected
in some patients at very low levels. B-Raf specific antibody responses did not correlate with clinical
parameters but in some cases, B-Raf antibodies emerged during disease progression.
Conclusion: These findings imply that B-Raf is immunogenic in melanoma patients and that it might
serve as a potential target for immunotherapy. However, B-Raf specific antibodies emerge at rather
late stages of melanoma progression and are present only with a low frequency indicating that
spontaneous B-Raf specific antibodies are not an early marker for melanoma, but rather may serve
as a therapeutic target.
Background
Cutaneous malignant melanoma is responsible for 1% of
all malignant tumors with a rising incidence in the Cauca-
sian population [1]. Initial diagnosis is based on asymme-
try, border regularity, multiple colours, diameter as well as
elevation of the pigmented lesion. However, it is some-
times difficult to differentiate between irregular dysplastic
nevi and a melanoma without histological analysis. Hith-
erto risk groups for the development of melanoma are
characterized by fair skin, multiple and/or dysplastic nevi
and the history of sunburns in childhood [2]. Invasive
melanomas have a rapid tendency to metastasize. In these
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stages of disease, therapy is very difficult and the 5-year
survival rate of stage IV patients is below 20% [3].
On the molecular level, melanoma is associated with sev-
eral genetic changes, including mutations or transcrip-
tional variations in tumor suppressors like p53, CDKN2A/
p16, CDKN1A/p21 or in oncogenes like N-Ras [4].
Recently, it has been discovered by Davies et al. that 66%
of melanoma have a mutated BRAF gene which results in
higher kinase activity due to a single amino acid exchange
(B-Raf V599E) occurring in almost 90% of the mutations
[5]. Most interestingly, this mutation is somatic [6,7] and
some authors describe the presence of the mutation
already in benign nevi [8], whereas others fail to repro-
duce the high frequencies in early stages and speculate of
mutated B-Raf being relevant for progression rather than
initiation of melanoma [9]. Nevertheless, the high inci-
dence of the mutations in melanoma qualify the B-Raf
protein as a potential target for tumor therapy and prelim-
inary results of phase II clinical trials with Raf kinase
inhibitors suggest protective activity [10].
Promising results with new approaches for melanoma
therapy have been obtained with active immunizations
against tumor associated antigens (TAA) like MAGE-3
[11], MART-1 [12-14] tyrosinase [15] or survivin [16].
Regarding the high incidence of B-Raf mutations and the
increased expression level in tumors, B-Raf should be an
attractive target for immunotherapy [17] and most
recently, independent findings demonstrated mutation
specific CD4+ T-cell responses in melanoma patients [18].
Moreover, we have recently demonstrated CD8+ T-cells in
melanoma patients reactive against an HLA B27 restricted
B-Raf V599E epitope encompassing the mutation identi-
fied using computer assisted algorithms [19]. However,
assessing CD4+ or CD8+ T-cell responses is not suitable for
screening larger numbers of patients to estimate
responder frequencies.
To determine the frequency of B-Raf specific responses in
melanoma patients and to evaluate whether B-Raf specific
immune responses could serve as a melanoma marker we
examined the Raf specific humoral response using an
ELISA assay with purified recombinant B-Raf, B-Raf
V599E or C-Raf protein.
Methods
Participants
Patient sera were obtained from frozen stocks and were
collected over a period of 5 years. All patients gave
informed consent to use their sera for scientific analysis.
Control sera were obtained from patients of the dermatol-
ogy department without signs of melanoma. Control
patients were fully anonymized and no further informa-
tion is available.
Antigens for ELISA
Recombinant wild type B-Raf, B-Raf V599E and C-Raf pro-
teins were expressed in Sf9 cells and purified as GST
fusions (B-Raf V599E, C-Raf) or His-tagged proteins (B-
Raf) as described [20]. Purity of the Raf kinase prepara-
tions was controlled by SDS-polyacrylamide gel electro-
phoresis and staining with Coomassie Blue.
ELISA
372 sera of melanoma patients were analyzed for B-Raf
V599E specific response, 271 sera were analyzed for B-Raf
wt and C-Raf specific responses and 119 sera of non
melanoma control patients of the dermatology depart-
ment were used and analyzed for B-Raf V599E, B-Raf wt
and C-Raf specific responses. For determination of serum
levels of total Ig or IgG, an ELISA assay was developed. 1
µg/ml of purified B-Raf, B-Raf V599E or C-Raf protein in
100 µl coating-buffer or buffer alone as background con-
trol (carbonate buffer, pH 9,6) was coated on NUNC 96-
Well MaxiSorp plates at 4°C overnight. Plates were
washed twice with washing buffer (0,05% Tween (Sigma)
in PBS) and blocked with 1% BSA (Sigma) in PBS. After
washing twice, serial dilutions of human sera, starting at
1:100, in 100 µl conjugate buffer (1% BSA, 0,05% Tween
in PBS) were incubated for 1.5 hours at 37°C. After four
wash steps, alkaline phosphatase coupled goat anti
human Ig (IgM + IgA + IgG, Dianova) or goat anti human
IgG (Dianova) diluted 1:2000 in 100 µl conjugate buffer
was added. After 1 h at 37°C and two washing steps, 50 µl
of pNPP (Sigma) substrate in buffer was added. The reac-
tion was incubated at room temperature and stopped after
20 min by 50 µl 1 M NaOH. Optical density was read at a
wavelength of 405 nm (OD405) in a TECAN Spectra
Thermo microplate reader.
For determination of specificity, a similar protocol was
used, but plates were coated with different concentrations
of antigen (0, 0.1, 1.0 and 2.0 µg/ml antigen in coating
buffer). Each concentration was determined in duplicate.
In addition, specificity was further confirmed using an
unrelated antigen, prostate specific antigen (PSA, Sigma),
at concentrations of 1 µg/ml for ELISA analysis. Two
patients exhibited non-specific serum responses and were
excluded from further analysis.
For competition ELISA performed with some positive
sera, a similar protocol was engaged, using a fixed dilution
of the sera and B-Raf or B-Raf V599E antigen for coating.
Competition was performed by adding different concen-
trations of B-Raf or B-Raf V599E (0.0, 0.1, 1 or 2 µg/ml) to
the human sera at the corresponding incubation step.
Data analysis
For the analysis of the ELISA data, the titer of the sera was
defined as the last serial dilution with an OD405 valueBMC Cancer 2004, 4:62 http://www.biomedcentral.com/1471-2407/4/62
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exceeding the Cut Off 0.275, corresponding to the mean
+ 1.5 SD of the background values of positive sera at
serum dilutions of 1:50. Raf specific titers were compared
to the background values using a two tailed Mann-Whit-
ney U test with a 95% confidence interval. The amount of
positive sera within the two groups were defined as sera
exceeding a given titer; the final definition of positive sera
were sera with titers of 1:300 or higher. Frequencies of
positive sera were compared using two sided Fisher's exact
test with 95% confidence interval.
Results and discussion
372 sera of 148 melanoma patients and sera of 119 con-
trol patients were screened for Raf specific antibody
responses by an ELISA assay using a secondary antibody
directed against IgG, IgA and IgM. Serial dilutions of the
sera were analysed for their OD405 and titers were attrib-
uted as described using a cut off OD405 of 0.275 (fig. 1A
and 1B). Positive sera reacted against B-Raf or B-Raf
V599E, but not against an unrelated antigen (fig. 1A). Spe-
cificity was further confirmed by coating the ELISA plate
using different concentration of the antigen (fig. 1C) and
WESTERN Blot analysis (additional figure 1 [see addi-
tional file 1]). In some positive sera analysed for IgG anti-
bodies, very weak B-Raf specific titers could be detected
(fig. 1D), but most sera were negative for specific IgG anti-
bodies (data not shown). Some positive sera were addi-
tionally tested for specificity for the mutated epitope using
a competition ELISA by coating B-Raf or B-Raf V599E and
competing Raf specific human antibodies by titrating in
unbound B-Raf or B-Raf V599E (fig. 2A,2B,2C). In all
cases tested, competition was achieved in every combina-
tion at corresponding antigen concentrations, whereas a
control serum with non-specific reactivity (fig. 2D)
showed no competition as expected. Taken together these
results demonstrate the presence of Raf specific antibod-
ies. In most cases, titers against B-Raf and B-Raf V599E
were consistently higher compared to titers for C-Raf (fig.
1B); only some weakly positive sera showed a response
dominated by C-Raf antibodies and in a minority of pos-
itive sera the specific response was equilibrated. Even
though antigen preparations were not checked for biolog-
ical activity and correct refolding and therefore a direct
comparison between C-Raf and B-Raf specific antibody
levels based on these assays is difficult, the data suggest
that the Raf specific antibody response in patients is
mainly directed against B-Raf. The moderate cross reactiv-
ity against C-Raf but not against an unrelated antigen
might be explained by the high conformational and
sequence similarity between Raf family members. In con-
trast, the differences observed between the reactivity
against B-Raf or B-Raf V599E are weak (fig. 1B) and sug-
gest that B-Raf and B-Raf V599E are recognized to a simi-
lar extend. This notion is further strengthened by the
results of the competition ELISA which failed to detect any
differences in the pattern of competition for a given serum
regardless of the antigen combination used (figure 2).
Therefore we conclude that the antibodies can not dis-
criminate between the naïve or the mutated form of B-Raf.
Comparison between Raf specific antibody responses in
sera from melanoma patients and control patients reveals
apparent differences (figure 3). Raf specific responses are
significantly different from background values for
melanoma patients and all Raf variants tested (two tailed
Mann-Whitney U test). In contrast, the difference
observed within the control group is not significant
(Mann-Whitney U test). However, reactivity against C-Raf
is rather weak in all sera tested and only 5 of 271 tested
sera from melanoma patients reach C-Raf specific titers of
1:300. A comparison between the percentage of patients
with B-Raf specific antibody levels above a given titer
reveals that sera derived from melanoma patients show
consistently higher values compared to the control group
(fig. 4A). In contrast, the frequency of C-Raf specific
responses are only marginally higher in the melanoma
population and not detectable at titers above 1:300. If
positive response is defined as sera with titers of 1:300 or
higher, 2.5% of the control group is positive for B-Raf and
1.68% for B-Raf V599E antibodies (fig. 4B). However,
5.41% (P = 0.12, Fisher's exact test) and 8.86% (P = 0.028,
Fisher's exact test) of sera derived from melanoma
patients were positive for B-Raf V599E and B-Raf respec-
tively (fig. 4B). Using this cut off, no control patients
could be identified with C-Raf specific antibodies, and
only 1.85% (P = 0.329, Fisher's exact test) of the
melanoma patients had detectable C-Raf specific antibod-
ies (fig. 4B). These results suggest that melanoma is asso-
ciated with higher rates of patients with detectable B-Raf
specific antibody responses. The difference between the
values obtained for B-Raf V599E and B-Raf specific anti-
bodies, which is expressed in lower scores for B-Raf
V599E, is most probably due to differences in the antigen
preparation and is less likely due to different specificity as
in most cases the scores against B-Raf V599E are in the
same range as the scores against B-Raf (see figure 1B),
whereas the C-Raf response consistently shows much
lower titers in positive cases and a different shape of the
curve (figure 1B). Taken together, these data strongly sug-
gest that 8.9% of melanoma patients have a B-Raf specific
antibody response and 2.5% of the control patients. At
this stage, it is far too early to foresee the consequences of
this finding for diagnostics or therapy of melanoma. All
melanoma patients were in a very advanced, rapidly pro-
gressing stage with high tumor loads (stage IV) and conse-
quently the presence of antibodies was not correlated with
survival (data not shown). However, at least some
patients had low but detectable levels of B-Raf specific IgG
antibodies which is in line with the independent finding
of B-Raf V599E specific T-cells in melanoma patients [18].BMC Cancer 2004, 4:62 http://www.biomedcentral.com/1471-2407/4/62
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Raf specific antibody response in different patients' sera Figure 1
Raf specific antibody response in different patients' sera. Analysis of 2 representative positive (42) and negative (12) 
sera using a secondary antibody detecting human IgG, IgA and IgM is depicted in A. Sera no. 42 and 12 were tested for specifi-
city against B-Raf, B-Raf V599E (V599E), an unrelated antigen (PSA) and without the addition of antigen (-). Serum 42 reacted 
against B-Raf and B-Raf V599E and not against an unrelated antigen. Sera 12 showed no measurable response. Sera withdrawn 
at different time points from patient no. 106 were tested at different dilutions in an ELISA and OD405 was determined (B). In 
the case of this patient, sera were negative at the first two time points and became strongly positive within three months. Spe-
cificity of the response was confirmed using different concentrations of antigen for coating (0, 0.1, 1 and 2 µg/ml) and different 
serum dilutions (C). All 371 patient and 119 control serum samples were analysed in a similar way. In D, serum was analyzed in 
a similar way then in C using an IgG specific secondary antibody. Serum #42 is weakly positive for B-Raf specific IgG antibodies, 
serum #1 is representative for most other sera of healthy donors and melanoma patients which are negative for B-Raf specific 
IgG antibodies.BMC Cancer 2004, 4:62 http://www.biomedcentral.com/1471-2407/4/62
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Another interesting point to note is the small, although
not significant, number of control patients with detecta-
ble levels of Raf specific antibodies. At least two out of 119
control patients showed a very strong B-Raf specific
response in the same range as we have observed for posi-
tive melanoma patients (figure 3). Due to the design of
the study, no information is available for this patient
group. Serum was sampled during diagnostic procedures,
therefore other underlying diseases as a cause for Raf spe-
cific antibodies cannot be excluded, including autoim-
mune diseases or neoplastic diseases of different origin.
Furthermore, as the control group has been sampled in
the dermatology department, this group might contain
patients with high numbers or irregular melanocytic nevi
or even unrecognised melanoma.
For different extracellular tumor antigens, including gan-
gliosides, in melanoma, positive associations between the
induction of IgM and IgG antibodies and survival time
have been reported [21] and the protective effect was
attributed to antibody dependent cellular toxicity [22].
Therefore, the induction of Raf antibodies might be a
favourable goal for the design of melanoma vaccines.
However it is questionable whether humoral responses
Competition ELISA to test for specificity for mutated B-Raf Figure 2
Competition ELISA to test for specificity for mutated B-Raf. ELISA was performed using 2 positive sera from 
melanoma patients (A, B) and 1 positive sera from the control group (C) as well as a human serum with known background 
reactivity (D; serum from a non-melanoma patient of the dermatology department with reactivity against BSA used for block-
ing). Plates were coated with B-Raf (■ , ▲ ) or B-Raf V599E (▼ , ◆ ) and competition was performed by titrating in increasing 
concentrations (0.0, 0.1, 1.0 and 5.0 µg/ml) of B-Raf (■  ▼ ) or B-Raf V599E (▲ , ◆ ). Data is presented using relative OD405 val-
ues that are adjusted relative to the first experimental OD values of the corresponding dataset. For the positive sera with spe-
cific Raf antibodies (A-C), competition reveals no differences between B-Raf and B-Raf V599E regardless of the combination 
suggesting that the antibodies can not discriminate between wt and mutated B-Raf. In contrast, the non-specific serum no. 79 
showed, as expected, no sign of competition with whatever antigen combination. n.d. not determined.BMC Cancer 2004, 4:62 http://www.biomedcentral.com/1471-2407/4/62
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against an intracellular antigen like Raf will have an effect.
In this respect it is interesting to ask why responses against
intracellular antigens like Raf or survivin [23] can be
observed at all. The most straightforward explanation,
which is particularly likely for advanced stage IV
melanoma patients, relies on the fact that the partial
necrosis of big tumor masses allows the crosspresentation
of intracellular proteins. The longitudinal analysis of our
patients, e.g. the one depicted in figure 1, illustrates, that
the occurrence of humoral immune responses was corre-
lated rather to tumor burden than therapeutic measures,
since the conversion occurred during the period when no
therapy was applied.
As oncogenic mutation of B-Raf and even transformation
by other oncogenic events is frequently accompanied by
Raf overexpression, the induction of an antibody response
is not necessarily due to the presence of the mutation.
Even though a polyclonal IgM response is very unlikely to
be specific for a point mutation, this notion would
explain the lack of specificity for the mutational epitope.
However, it is also possible that a cellular immune
response prior to the induction of Raf specific antibodies
has occurred. Such a T-cell response directed against Raf or
other tumor antigens, would also result in the lysis of
tumor cells and the liberation of intracellular antigens. It
is important to mention that the lysis leading to the
Comparison of B-Raf V599E, B-Raf and C-Raf specific antibody responses between control patients or melanoma patients Figure 3
Comparison of B-Raf V599E, B-Raf and C-Raf specific antibody responses between control patients or 
melanoma patients. The comparison has been performed between 119 control sera with 371 sera of melanoma patients 
tested for B-Raf V599E and 272 sera of melanoma patients tested for B-Raf and C-Raf. Titers correspond to the last serial dilu-
tion of the patients sera exceeding a cut-off OD405 of 0.275. Compared to the background values in the absence of antigen 
(control -; melanoma -), the difference is not significant for control patients (P = 0.232; 0.471; 0.4054 for B-Raf V599E, B-Raf wt 
and C-Raf respectively, two tailed Mann-Whitney U test) and significant for melanoma patients (P = 0.012; 0.0009; 0.0022 for 
B-Raf V599E, B-Raf wt and C-Raf respectively, two tailed Mann-Whitney U test).BMC Cancer 2004, 4:62 http://www.biomedcentral.com/1471-2407/4/62
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formation of antibodies against intracellular antigens can
be caused by T-cells other than the already observed B-Raf
V599E specific CD4+ or CD8+ T-cells. This question still
remains to be clarified as up to now only advanced stage
patients have been examined. It is obvious that at this
stage the occurrence of antibodies is not correlated with
prognosis and that it is very unlikely that the antibody
response itself will have an influence on the disease. How-
ever, as it is rather unlikely that the frequency of a B-Raf
specific T-cell response exceeds the frequency of antigen
responses, our data can help to set the upper limit for the
expected frequency of B-Raf or B-Raf V599E specific T-cells
as 8.5% which allows the rational design of search strate-
gies especially for Raf specific CD8+ T-cells.
Even though the detection of B-Raf specific humoral and
T-cell responses suggest that B-Raf/B-Raf V599E is immu-
nogenic and that a response could be induced in at least a
part of the patients, this notion does not allow conclu-
sions on its suitability as a target for immunotherapy per
se. In theory, an optimal tumor antigen is exclusively
expressed in the tumor tissue and essential for tumor cell
growth and survival to avoid the emergence of escape
mutants or antigenic loss, whereas the immunological
attack of the tumor cell is independent of the function of
the antigen [17]. To date, many TAA used for the immu-
notherapy of melanoma including MAGE [24] or tyrosi-
nase provide no obvious advantage to the tumor cell and
therefore there is no pressure to retain the antigen. In
contrast, mutated B-Raf has a high prevalence in
melanoma and the consequences of its activation, includ-
ing induction of proliferation and block of apoptosis are
well known. However, it is still a matter of debate whether
B-Raf activity mainly drives melanoma initiation or
whether its function is also relevant for later stages. The
first conclusion is supported by studies demonstrating
that the mutations already occur in melanocytic nevi at
frequencies comparable to late stage melanoma [8], are
not correlated with clinical outcome [25] and finally the
Raf inhibitor Bay 43-9006 seems to have only moderate
efficiency in advanced melanoma as reported by Ahmed
et al. during the ASCO meeting 2004 [26]. However, other
studies correlated B-Raf mutations with progression rather
then initiation [9] and we and others suggested a role for
B-Raf as a negative prognostic factor in metastatic
melanoma [25,27]. Despite these conflicting data on the
Fraction of sera positive at different antibody levels Figure 4
Fraction of sera positive at different antibody levels. In A, the percentage of B-Raf positive sera of control patients () 
or melanoma patients (■ ) is plotted as a function of the cut off titer, whereas sera are termed positive if the titer reaches or 
exacerbates the given cut off titer. The difference between control patients and melanoma patients was statistically significant 
for a cut off titer of 1:300 (P = 0.028; 0.073; 1.0, two sided Fisher's exact test for cut off titers equal to 1:300; 1:900 and 1:2700 
respectively). In B, the percentage of sera with titers higher or equal than 1:300 is shown for B-Raf V599E, B-Raf and C-Raf spe-
cific responses. In all cases, the amount of antibody positive melanoma patients is higher compared to the control group. This 
trend was significant for the comparison of B-Raf positive sera (P = 0.028, Fisher's exact test) and not significant for the com-
parison of B-Raf V599E (P = 0.12, Fisher's exact test). However, C-Raf specific antibodies with titers of 1:300 were only detect-
able in 1.8% of the tested sera from melanoma patients and none of the control patients (P = 0.327).BMC Cancer 2004, 4:62 http://www.biomedcentral.com/1471-2407/4/62
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clinical relevance of mutated B-Raf at late stages, the high
prevalence would already justify to evaluate B-Raf/B-Raf
V599E as a target for immunotherapy, as this prevalence
is in the same range as for the TAA currently used without
any evident advantage for tumor cell growth.
Conclusions
Taken together we have demonstrated that B-Raf/B-Raf
V599E specific antibodies are detectable in 8.9% of
advanced stage melanoma patients and B-Raf V599E
might therefore be a valuable target for immune therapy.
Combined with the independently described B-Raf V599E
specific CD4+  and our earlier demonstration of B-Raf
V599E specific CD8+ T-cell responses this study makes the
screening for novel B-Raf V599E MHC class I epitopes for
vaccination approaches a promising task.
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